Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856012 | 1.00 | HCAR2 (0.48) | HCAR2ATMALDH1A1NPSR1LMNA | |
| SCHEMBL7045739 | 1.00 | HCAR2 (0.48) | HCAR2ATMALDH1A1NPSR1LMNA | |
| SCHEMBL6524281 | 1.00 | HCAR2 (0.48) | HCAR2ATMALDH1A1NPSR1LMNA | |
| SCHEMBL13724883 | 1.00 | HCAR2 (0.48) | HCAR2ATMALDH1A1NPSR1LMNA | |
| SCHEMBL20562242 | 0.92 | HCAR2 (0.62) | HCAR2ATMALDH1A1NPSR1LMNA | |
| SCHEMBL20561333 | 0.92 | HCAR2 (0.62) | HCAR2ATMALDH1A1NPSR1LMNA | |
| SCHEMBL20562241 | 0.92 | HCAR2 (0.62) | HCAR2ATMALDH1A1NPSR1LMNA | |
| SCHEMBL20561334 | 0.92 | HCAR2 (0.62) | HCAR2ATMALDH1A1NPSR1LMNA | |
| SCHEMBL10865325 | 0.85 | MAPT (0.38) | HCAR2ALDH1A1NPSR1LMNAHSD17B10 | |
| SCHEMBL10865162 | 0.85 | MAPT (0.38) | HCAR2ALDH1A1NPSR1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019143560-A9 | METHODS FOR PROMOTING MITOCHONDRIAL BIOGENESIS IN NEURAL CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-12 | — | — | WO | claimed |
| WO-2019143560-A1 | METHODS FOR PROMOTING MITOCHONDRIAL BIOGENESIS IN NEURAL CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-25 | — | — | WO | claimed |
| US-20190111016-A1 | METHODS OF TREATING MUSCLE AND LIVER DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-18 | — | — | US | claimed |
| WO-2017147505-A1 | METHODS OF TREATING MUSCLE AND LIVER DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-31 | — | — | WO | claimed |
| WO-2019143560-A9 | METHODS FOR PROMOTING MITOCHONDRIAL BIOGENESIS IN NEURAL CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019143560-A1 | METHODS FOR PROMOTING MITOCHONDRIAL BIOGENESIS IN NEURAL CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20190111016-A1 | METHODS OF TREATING MUSCLE AND LIVER DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-18 | — | — | US | disclosed |
| US-20180333386-A1 | AGENTS USEFUL FOR TREATING FRIEDREICH'S ATAXIA AND OTHER NEURODEGENERATIVE DISEASES | IXCHEL PHARMA LLC (US) | 2018-11-22 | — | — | US | disclosed |
| WO-2017147505-A1 | METHODS OF TREATING MUSCLE AND LIVER DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-31 | — | — | WO | disclosed |
| EP-3022188-B1 | PIPERAZINE SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-07 | — | — | EP | disclosed |
| EP-3013817-B1 | DIFLUOROETHYL-OXAZOLE SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-26 | — | — | EP | disclosed |
| EP-2850058-B1 | 1-(P-TOLYL)CYCLOPROPYL SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-07-13 | — | — | EP | disclosed |
| WO-2013171687-A1 | 1-(P-TOLYL)CYCLOPROPYL SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-21 | — | — | WO | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-05 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012149478-A2 | AGENTS USEFUL FOR TREATING FRIEDREICH'S ATAXIA AND OTHER NEURODEGENERATIVE DISEASES | SERKET PHARMA, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333386-A1 | AGENTS USEFUL FOR TREATING FRIEDREICH'S ATAXIA AND OTHER NEURODEGENERATIVE DISEASES | CLN6, NLN, HTT | HCAR2 3305/4885ATM 1482/4885ALDH1A1 2592/4885 |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | HCAR2 23/4885ATM 4427/4885ALDH1A1 1293/4885 |
| US-20190111016-A1 | METHODS OF TREATING MUSCLE AND LIVER DISORDERS | CKMT1A; CKMT1B, CPT1B, GLS2 | HCAR2 2186/4885ATM 4219/4885ALDH1A1 860/4885 |
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ADH1A, ADH1C, NAPA | HCAR2 558/4885ATM 3999/4885ALDH1A1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.